Labcorp Holdings Inc. (LH) Income Statement

The sequential improvement in revenue growth, from 4.6% in 2024Q1 to 5.8% in 2026Q2, indicates a strengthening demand environment, likely driven by increased test volumes and favorable mix. The 7.2% TTM growth, as reported in the latest quarterly data, appears to be organic, given the absence of major acquisitions in the period. This pace, while modest, is consistent with a mature healthcare services provider benefiting from stable physician ordering patterns and the ongoing shift toward higher-value testing.

The gross margin expansion of 160 basis points over the period suggests that Labcorp is successfully offsetting reimbursement cuts through operational efficiencies and a favorable test mix, with a growing contribution from esoteric and genomic testing. However, the margin remains below Quest Diagnostics' 31.9%, indicating potential for further improvement. Investors should monitor whether this expansion is sustainable, as the company's ability to pass on cost increases is limited by fixed reimbursement schedules.

The 200 basis point improvement in operating margin, coupled with a 50 basis point reduction in SG&A intensity, suggests that Labcorp is beginning to realize operating leverage as revenue scales. This is particularly notable given the high fixed-cost nature of the business, where incremental volume drops through to operating income. The trend appears to be driven by disciplined cost management and the integration of prior acquisitions, which may continue to support margin expansion if revenue growth persists.

The reduction in COGS intensity suggests that Labcorp is benefiting from scale and automation, which is critical in a labor-intensive industry. SG&A has been relatively stable, indicating that the company is not aggressively investing in sales and marketing, which may be appropriate given its established market position. However, the lack of R&D spending (reported as zero) is notable, as it may indicate that the company is relying on external innovation or that R&D is embedded in other lines, which could be a concern for long-term growth.

The 2025Q4 dip in net income and EPS, despite stable revenue, suggests a significant one-time charge, likely related to the Fortrea spin-off or asset impairments. This inflection point is critical because it may have distorted the trailing twelve-month earnings, and investors should normalize for this to assess the true earnings power. The subsequent recovery in 2026Q1 and Q2, with EPS reaching $3.35 and $3.64, indicates that the underlying business remains healthy and that the one-time items are not indicative of ongoing operations.